echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Express Merck returns to the field of Alzheimer's disease, reaching about 1.1 billion US dollars in research and development cooperation

    Express Merck returns to the field of Alzheimer's disease, reaching about 1.1 billion US dollars in research and development cooperation

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Edited by WuXi AppTec Content Team

    Cerevance announced today that it has entered into a multi-year strategic research and development cooperation with Merck & Co.



    Alzheimer's disease is the most common neurodegenerative disease in the elderly.


    ▲Introduction to the NETSseq technology platform (Image source: Cerevance's official website)


    [1] Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer's Disease.



    Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.